Human Phenotype Ontology (HPO) terms are increasingly used in diagnostic settings to aid in the characterization of patient phenotypes. The HPO annotation database is updated frequently and can provide detailed phenotype knowledge on various human diseases, and many HPO terms are now mapped to candidate causal genes with binary relationships. To further improve the genetic diagnosis of rare diseases, we incorporated these HPO annotations, gene-disease databases, and gene-gene databases in a probabilistic model to build a novel HPO-driven gene prioritization tool, Phen2Gene. Phen2Gene accesses a database built upon this information called the HPO2Gene Knowledgebase (H2GKB), which provides weighted and ranked gene lists for every HPO term. Phen2Gene is then able to access the H2GKB for patient-specific lists of HPO terms or PhenoPackets descriptions supported by GA4GH
Introduction
Rapid and accurate genetic diagnosis of Mendelian diseases is necessary to optimize both treatment and management strategies and implement precision medicine. Compared to traditional single-gene tests or gene panels, recent efforts have utilized next-generation sequencing (NGS) technologies, such as whole exome sequencing (WES) and whole genome sequencing (WGS). The intent of the NGS effort is to improve diagnostic rates, enhance time efficiency and decrease overall financial burdens [1] [2] [3] [4] [5] . However, due to the substantially larger pool of candidate genes created by NGS data, sequence interpretation has become a major hurdle in diagnostic settings. Computational approaches that streamline the diagnostic workflow and shorten the analytical turnaround time are needed.
The Human Phenotype Ontology (HPO) database 6 associates human diseases with phenotypic abnormalities. These terms possess ever-increasing interoperability with other ontologies [7] [8] [9] [10] [11] and allow for computational deep phenotyping, making it the prevailing standard terminology for human phenotypes. We have developed a few computational tools [12] [13] [14] that use phenotype data for gene prediction and prioritization. Although these methods are useful, they cannot provide real-time decision support in clinical settings; for example, users may need to add or remove one phenotype term for a patient and immediately observe how the candidate gene list changes.
Recent studies have shown the utility of incorporating phenotype data such as HPO terms in identifying causal genes from NGS data, which increases time efficiency and diagnostic yields 15 . There are phenotype analysis tools that use HPO terms to prioritize candidate causal genes: Phevor 16 , VarElect 17 , and OVA 18 . These HPO terms can be supplied by diagnostic labs, clinical geneticists, doctors, or natural language processing (NLP) algorithms that parse doctors' notes such as Doc2HPO 14 . The prioritized list of genes can then be combined with NGS data to identify potential disease genes. The downside of these tools, however, is that they require gene lists beforehand, take longer to prioritize genes, they can only be used via web interface, and have no open source code. Thus, such tools cannot be implemented on a large scale, and cannot be integrated into existing clinical diagnostic workflows, which are often protected within institutional firewalls.
We present a new rapid, accurate, phenotype-based gene-prioritization tool called Phen2Gene. Phen2Gene takes HPO terms for a patient and generates a patient-specific ranked list of candidate genes using our precomputed database, the HPO2Gene Knowledgebase (H2GKB), in a mere second. Unlike existing binary HPO-gene annotations in the HPO annotation database, the H2GKB is a new database that links each HPO term to its own ranked list of candidate genes, each with a confidence score. These scores represent a substantial accuracy improvement over the previous version of Phenolyzer. We also provide open source code under the MIT license, together with a web server for downloading and accessing the H2GKB, and a RESTful API web service for automated queries of phenotype terms with JSON output.
Methods

Acquiring Patient-Specific Gene Lists with Phen2Gene
Physicians can manually curate HPO terms for their patients, which is becoming more common, or feed the patients' notes into Doc2HPO to discover the relevant and negated HPO terms for the patient's phenotype. Doc2HPO is a public tool that uses multiple NLP tools and algorithms to parse patient notes into HPO terms. HPO terms act as the sole form of input into Phen2Gene which then searches the H2GKB for each term's ranked gene list.
All HPO terms under the root term 'Phenotypic abnormality' (HP:0000118) are recognizable by Phen2Gene. By default, Phen2Gene weights the inputted HPO terms by skewness of gene scores, as some HPO terms possess more precise information content than others 19 . Then, Phen2Gene searches the H2GKB for each input term's gene list and sorts and ranks all the genes based on their ranks in each term's list and the weight of each HPO term to produce a final, ranked candidate gene list ( Figure 1 ).
HPO2Gene Knowledgebase Construction
In order to construct the H2GKB, we first extract every term from the Human Phenotype Ontology Database, underneath the root term 'Phenotypic abnormality' (HP:0000118) ( Figure  2a ). For each HPO term, we run an enhanced version of Phenolyzer (ver. 0.4.0), dubbed Enhanced Phenolyzer, which incorporates HPO-gene annotations from the Jackson Laboratory 6 , and gene-disease annotations from OMIM 20 , ClinVar 21 , Orphanet 22 , and GeneReviews 23 . It then adds information from gene-gene databases HPRD 24 , NCBI's Biosystems Database 25 , HGNC Gene Family 26 , and HTRI 27 , and prioritizes and outputs the associated genes. This generates a ranked list of candidate causal genes for each HPO term, which are then consolidated into the H2GKB ( Figure 2b ). This precomputed H2GKB can then be rapidly accessed by Phen2Gene and used to rank lists of genes for individual patients. The H2GKB is also freely available online and downloadable from the Phen2Gene web server. 
Enhanced Phenolyzer
The original version of Phenolyzer (ver. 0.2.2) processed free-text terms supplied by users. We updated the databases inside Phenolyzer, incorporated new HPO-gene annotations from the Jackson Laboratory database, fixed some bugs, and released it as Enhanced Phenolyzer (ver. 0.4.0). Enhanced Phenolyzer contains a new function to turn HPO terms into a list of genes, by generating a prioritized gene list for each HPO term. Unlike the original Phenolyzer, Enhanced Phenolyzer first generates two seed gene sets. Seed Gene Set 1 is built on HPO-gene annotation files downloaded from the Jackson Laboratory for Genomic Medicine available at https://hpo.jax.org/app/download/annotation , while Seed Gene Set 2 construction follows the method outlined in the original Phenolyzer paper, which translates phenotype terms to disease names, and incorporates the five precompiled gene-disease databases to search for seed genes.
Candidate Genes Prioritization
For seed genes in Set 1, we gave an equal score to each gene and HPO term pair, , S 1 Gene , ( j HP i) = 1 since JAX annotation only lists genes for each individual HPO term, but without quantitative scores representing the strength of associations.
In Set 2, we followed the calculation method in the original Phenolyzer for each seed gene using gene-disease databases associated with each individual HPO term, and noted as .
We sum up the two scores,
and normalized it to a range between 0 and 1 as the final seed gene score, .
In the following steps, we used the original Phenolyzer's method for expanding the list of candidate genes and reprioritizing the seed gene list using gene-gene databases. Then we generated the HPO2Gene-KB with Enhanced Phenolyzer.
Weighting by Skewness
We calculated the skewness value for the distribution of all gene scores for each HPO term, and used it multiplicatively to adjust the weights of HPO terms individually. The gene score distributions vary widely from term to term. The gene score distributions of "Seizures" (HP:0001250) and "Cleft palate" (HP:0000175) demonstrate the difference in the specificity of HPO terms ( Supplementary Figure 1 ) . "Cleft palate" has a positively skewed gene score distribution compared to "Seizures." For "Cleft palate," most genes have a near zero raw score value, but for seizures the mean and standard deviation are much larger. We assume that the more skewed the gene score distribution, the greater the difference between high and low ranking genes. This discrepancy provides HPO terms with better information for their associated genes. Thus, we used Pearson's moment coefficient of skewness to represent the skew and weight HPO terms' gene weights:
and where is the skewness of the gene-score distribution of , which we kewness(HP ) s j HP j calculated with Python 3.8 and the SciPy 1.3.1 stats module. We also created alternative weighting schemes involving no weight or informational content ( Supplemental Methods ). 
Gene Score Computation with Weighted HPO Terms
where is the assigned weight as illustrated in the previous section, is W HP
All of genes are sorted by their scores in descending order.
HP j
Results
General Use
Since the H2GKB is precomputed, the results for Phen2Gene are instant. The weight given to the HPO terms can be chosen or defined by the end user. The terms can be unweighted, weighted by ontology-based information content, or the skewness of gene scores for each HPO term, which is the recommended default. No prior gene list knowledge is required, and if a physician has no candidate genes, or if whole exome or whole genome sequencing cannot be performed for practical reasons (such as insurance reimbursement issues), it could help select a targeted sequencing gene panel to find variants causal for the phenotype. This process can be performed case-by-case on the web server, or using the Phen2Gene python script and thus can be scaled up massively to thousands of patients without prior gene knowledge, unlike competing HPO-to-gene software tools.
Accuracy Evaluation with Collected Expert-Curated Phenotype Data
For our benchmark testing of Phen2Gene, we used 282 de-identified patients who were diagnosed as carrying single disease gene as our study subjects. Their study data were from 5 different sources but 3 were manually curated, hence we divided them into 4 groups. Group 1 only contained one disease gene: TAF1, but the other three groups contained numerous known and previously validated disease genes ( Table 1 ). The phenotypes in these three groups were completely randomly chosen and the phenotypes are not necessarily related in any way.
An effective way to understand how well a phenotype-based gene prioritization tool performs is to have experts curate HPO terms and phenotype information for single-gene diseases. These experts also know the causal genes for these diseases, thus aiding in assessing if a tool is able to properly rank the causal gene highly.
Set
Data curation Where HPO terms are derived Each patient case in the benchmark data set has only a single causal gene that is known beforehand by the physicians who curated the patient data. This data was used to create the benchmark test between Phen2Gene and the original version of Phenolyzer ( Figure 3 ). Since Phen2Gene leverages the precomputed H2GKB, the speed-up in using Phen2Gene over Phenolyzer is substantial ( Table 2 ). The speed with which Phen2Gene can both access and rank gene information from the H2GKB, and the fact that it can be deployed in parallel, speaks to its scalability in future large-scale phenotype analysis studies. Proband has a condition with unknown genetic cause but several candidate variants annotated and filtered using ANNOVAR 104 . Clinical notes on the proband's condition are used by Doc2HPO to generate a list of HPO terms, which act as input for Phen2Gene or Phenolyzer. These tools rank several thousand genes and by intersecting them with the candidate list of genes overlapping the variants, we obtain a list of likely candidate genes for KGB syndrome, which is known to be caused by variants in ANKRD11, shown here.
General Use Case: Narrowing Down Candidate Genes For Undiagnosed Diseases
To demonstrate the real-world usage of phenotype-driven gene prioritization in clinical diagnostic settings, we performed a retrospective analysis on a previously published case. We were previously presented with a proband possessing a suspected Mendelian disease, and we performed whole exome sequencing on the proband and the parents. In a previous study, we identified a de novo , single-nucleotide insertion in ankyrin repeat domain 11 (ANKRD11) as the disease causal variant, and reached a genetic diagnosis of KBG syndrome, an extremely rare disease. In the current study, we evaluated whether Phen2Gene and Phenolyzer can facilitate automated gene finding from the exome data, by analyzing the proband only (i.e. without parental information).
We used the proband's HPO terms as input for Phen2Gene and the proband's disease and symptom terms as input for Phenolyzer. The causal gene, ANKRD11, was initially ranked 2nd and 5th by Phen2Gene and Phenolyzer, respectively, among all the genes in the genome. We intersected these gene lists with the list of candidate genes derived from genes that harbor at least one rare, protein-altering variant in the patient. ANKRD11 was ranked 1st by both Phen2Gene and Phenolyzer. This example shows how both Phen2Gene and Phenolyzer can be used to rank a causal gene in the top 10 genes based on disease and symptom information and the list of candidate genes extracted from exome sequencing. Thus human reviewers, such as clinical geneticists or genetic counselors, can review the top 10 or 50 genes and reach a genetic diagnosis with great expedition, or combine the top 1000 genes with variant information to shorten their lists of candidate genes.
Discussion
Phen2Gene represents a change to the catalog of phenotype-to-gene software. Currently, to the best of our knowledge, no other such tool allows for scalability to thousands of patients, and often they have slow web servers that require copy-and-paste input, for one patient at a time. In addition, other tools that rank genes based on HPO terms have no open source code available -their work cannot be easily checked or improved upon by the community. In comparison, Phen2Gene is extremely fast, does not require prior gene knowledge, and does not need to be run on a web server, though the provided server is also faster than competitors' servers. We further provide the H2GKB and the benchmark data as freely downloadable files. Compared to the annotation file that documents about 20 binary relationships between HPO terms and genes on average from Jackson Laboratory's HPO website, the H2GKB we provide here contains weighted relationships between each HPO term and hundreds or even thousands of genes. Phen2Gene shows marked improvement over the original version of Phenolyzer, and in our future work we plan to greatly improve Phenolyzer and expand upon the H2GKB, increasing performance.
Another benefit of Phen2Gene is that it is variant agnostic. Structural variants and repeat expansions in intronic regions are known to cause disease 105, 106 , and on average, there are more than 20,000 structural variants (SVs) in the human genome 107 . Based on our calculation using the gold standard SV call set from HG002 108 and the gene annotation file from GENCODE (v25), more than half of the structural variants overlap with genes and most overlap intronic regions. The list of tools that can score structural variants or repeat expansions is extremely small, but Phen2Gene could used to narrow down a candidate variant list containing repeat expansions or SVs.
In the future, there are several concepts which we hope to address, not the least of which is a double counting bias ubiquitous to all such HPO-to-gene tools. Some doctors' notes may contain terms like myoclonic seizures, epilepsy and absence seizures, all of which represent three different HPO terms (HP:0002123, HP:0001250, and HP:0002121, respectively) for what is essentially the same combined condition. As a result, it may be biased towards terms mentioned more often in doctors' notes. This redundancy can be eliminated through manual HPO term input by human experts, but is still a common issue that needs to be addressed, perhaps by downweighting similar HPO terms.
Another issue we need to handle is the issue of negated terms such as "no seizures." Obviously, if experts input HPO terms manually, this is not a difficult issue to address, but for NLP algorithms that extract terms from doctors' notes, we could be adding false positive HPO terms if negation is not properly detected. Conversely, using negated HPO terms to lower the ranking of negated-term-associated genes is another useful incorporation of negated term data.
Integrating algorithms like DEEPEN 109 and NegEx 110 into tools such as Doc2HPO may help us solve this problem.
We could improve the granularity of the scoring algorithm by incorporating corpus-based information content. Phen2Gene could still be improved further, and one method for more properly assessing information content is to use HPO terms in tandem with a large body of clinical literature. This could enable us to give the proper weight to HPO terms or perhaps incorporate other terminology not covered by HPO, like UMLS, or NLP-derived classifications or clusters. There is a need for a more widely applicable terminology in the medical field, especially for diseases requiring deeper phenotyping, and this would become a useful resource for researchers doing similar work.
Finally, we can combine Phen2Gene with variant prioritization software or disease gene discovery tools such as CADD 111 , REVEL 112 , or CCR 113 , to further narrow down potential disease gene candidates. If a diagnostician has a list of genetic variants they are more likely to use one of these tools first. In the future, we hope to create a hybrid score that combines computationally derived variant scores with phenotype derived gene prioritization.
In summary, the H2GKB fills a void in the community in linking standardized phenotype terms to genes with weighted scores, and it may facilitate or inspire the development of novel computational tools that link HPO terms to genetic information, especially where whole exome/genome sequencing data is available. The Phen2Gene tool provided in this paper can rapidly access and rank this information. It has been implemented in Dx29 ( www.dx29.ai ) and Doc2HPO's pipeline so far, and we hope to deploy it in other similar web services. Through command line tools, web servers, and RESTful API web services, we believe that Phen2Gene will greatly facilitate and expedite phenotype-driven gene prioritizations for rare diseases.
Data Availability
The current version of Phen2Gene is 1.1.0. The source code and scripts for figures are available at https://github.com/WGLab/Phen2Gene . Additionally, we built a Phen2Gene Web Server available at http://phen2gene.wglab.org , to facilitate users who prefer to use web interface for gene prioritization. The current version of H2GKB is also downloadable at https://github.com/WGLab/Phen2Gene/releases/download/V1.1.0/H2GKB.tar.gz .
All the benchmark datasets are available in the Supplementary Materials of this manuscript. 
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